Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
50,571,171
-
Share change
-
+103,414
-
Total reported value
-
$1,391,721,257
-
Put/Call ratio
-
103%
-
Price per share
-
$27.52
-
Number of holders
-
139
-
Value change
-
-$661,540
-
Number of buys
-
71
-
Number of sells
-
62
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q3 2023
As of 30 Sep 2023,
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) was held by
139 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,571,171 shares.
The largest 10 holders included
FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, RTW INVESTMENTS, LP, BlackRock Inc., Kynam Capital Management, LP, VANGUARD GROUP INC, Polar Capital Holdings Plc, STATE STREET CORP, Bellevue Group AG, and Pictet Asset Management Holding SA.
This page lists
140
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.